Table 1.

Table of Anti–PD-(L)1 Agents Undergoing Investigation by Tumor Type

Agent	Target	NSCLC	SCLC	Mesothelioma	TET	Total
ABBV-181	PD-1	0	1	0	0	1
AK105	PD-1	2	0	0	0	2
Atezolizumab	PD-L1	77	22	5	1	105
Avelumab	PD-L1	11	0	1	1	13
BI 754091	PD-1	1	0	0	0	1
Camrelizumab	PD-1	20	3	0	0	23
Cemiplimab	PD-1	4	0	0	0	4
CS1001	PD-L1	1	1	0	0	2
Durvalumab	PD-L1	87	18	4	0	109
HLX 10	PD-1	2	1	0	0	3
KN046	PD-L1/CTLA-4	3	0	0	1	4
M7824	PD-L1/TGF-β	4	1	0	1	6
MGA-012	PD-1	1	0	0	0	1
Nivolumab	PD-1	118	18	12	2	150
Pembrolizumab	PD-1	158	13	16	6	193
Prolgolimab	PD-1	2	0	0	0	2
SHR-1316	PD-L1	2	4	0	0	6
Sintilimab	PD-1	18	5	0	0	23
Spartalizumab	PD-1	4	0	0	0	4
Tislelizumab	PD-1	8	2	0	0	10
Toripalimab	PD-1	12	5	0	0	17
TQB2450	PD-L1	4	2	0	0	6
TSR-042	PD-1	1	0	0	0	1

PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; TET, thymic epithelial tumor; TGF-β, transforming growth factor-β.